Pien F N Bosschieter1, Nico de Vries1,2,3,4, Reena Mehra5, Shalini Manchanda6, Tapan A Padhya7, Olivier M Vanderveken3,4, M J L Ravesloot1. 1. Department of Otorhinolaryngology-Head and Neck surgery, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands. 2. Department of Oral Kinesiology, Academisch Centrum Tandheelkunde Amsterdam MOVE Research Institute Amsterdam, University of Amsterdam and VU University Amsterdam, Amsterdam, The Netherlands. 3. Department of Otorhinolaryngology-Head and Neck Surgery Antwerp University Hospital (UZA), Antwerp, Belgium. 4. Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium. 5. Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio. 6. Division of Pulmonary, Critical Care, Sleep, and Occupational Medicine, Indiana University School of Medicine, Indianapolis, Indiana. 7. Department of Otolaryngology-Head and Neck Surgery, University of South Florida Morsani College of Medicine, Tampa, Florida.
Abstract
STUDY OBJECTIVES: Data on adherence and outcome of upper airway stimulation (UAS) for patients with obstructive sleep apnea (OSA) are collected in an international registry (ADHERE). Previous publications report significant improvement in self-reported and objective OSA outcomes, durable effectiveness, and high adherence. Debate remains whether the effectiveness of UAS is influenced by preoperative OSA severity; therefore, we aimed to evaluate this using data from the ADHERE Registry. METHODS: ADHERE is a postmarket, ongoing, international multicenter registry. Adult patients were included if they had undergone UAS implantation and had at least 1 follow-up visit recorded in the database on June 8, 2021. We divided the patients into 5 subgroups, based on OSA severity at baseline (AHI in events/h): subgroup 1 (0-15), 2 (15-30), 3 (≥ 30-50), 4 (> 50-65), and 5 (> 65). We compared results regarding objective and self-reported treatment outcomes. RESULTS: A total of 1,963 patients were included. Twelve months after implantation, there was a significant (P < .0001) improvement in objective sleep parameters in all subgroups with an AHI above 15 events/h. Patients in subgroup 1 had the lowest AHI at the final visit and the AHI reduction in patients in subgroup 5 was the largest (P < .0001). No significant difference was found between the subgroups in overall treatment success (66.6%) and improvement in self-reported outcomes. CONCLUSIONS: Our results suggest that UAS is an effective treatment for patients with an AHI ≥ 15 events/h, independent of preoperative OSA severity. Self-reported outcomes and treatment success did not differ significantly between the 5 subgroups. These results clearly support that the indication of UAS could be broadened for patients with an AHI above 65 events/h, which, to date, is not common practice. CLINICAL TRIAL REGISTRATION: Registry: ClinicalTrials.gov; Title: Adherence and Outcome of Upper Airway Stimulation (UAS) for OSA International Registry (ADHERE Registry); Identifier: NCT02907398; URL: https://www.clinicaltrials.gov/ct2/show/NCT02907398. CITATION: Bosschieter PFN, de Vries N, Mehra R, et al. Similar effect of hypoglossal nerve stimulation for obstructive sleep apnea in 5 disease severity categories. J Clin Sleep Med. 2022;18(6):1657-1665.
STUDY OBJECTIVES: Data on adherence and outcome of upper airway stimulation (UAS) for patients with obstructive sleep apnea (OSA) are collected in an international registry (ADHERE). Previous publications report significant improvement in self-reported and objective OSA outcomes, durable effectiveness, and high adherence. Debate remains whether the effectiveness of UAS is influenced by preoperative OSA severity; therefore, we aimed to evaluate this using data from the ADHERE Registry. METHODS: ADHERE is a postmarket, ongoing, international multicenter registry. Adult patients were included if they had undergone UAS implantation and had at least 1 follow-up visit recorded in the database on June 8, 2021. We divided the patients into 5 subgroups, based on OSA severity at baseline (AHI in events/h): subgroup 1 (0-15), 2 (15-30), 3 (≥ 30-50), 4 (> 50-65), and 5 (> 65). We compared results regarding objective and self-reported treatment outcomes. RESULTS: A total of 1,963 patients were included. Twelve months after implantation, there was a significant (P < .0001) improvement in objective sleep parameters in all subgroups with an AHI above 15 events/h. Patients in subgroup 1 had the lowest AHI at the final visit and the AHI reduction in patients in subgroup 5 was the largest (P < .0001). No significant difference was found between the subgroups in overall treatment success (66.6%) and improvement in self-reported outcomes. CONCLUSIONS: Our results suggest that UAS is an effective treatment for patients with an AHI ≥ 15 events/h, independent of preoperative OSA severity. Self-reported outcomes and treatment success did not differ significantly between the 5 subgroups. These results clearly support that the indication of UAS could be broadened for patients with an AHI above 65 events/h, which, to date, is not common practice. CLINICAL TRIAL REGISTRATION: Registry: ClinicalTrials.gov; Title: Adherence and Outcome of Upper Airway Stimulation (UAS) for OSA International Registry (ADHERE Registry); Identifier: NCT02907398; URL: https://www.clinicaltrials.gov/ct2/show/NCT02907398. CITATION: Bosschieter PFN, de Vries N, Mehra R, et al. Similar effect of hypoglossal nerve stimulation for obstructive sleep apnea in 5 disease severity categories. J Clin Sleep Med. 2022;18(6):1657-1665.
Authors: Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke Journal: Ann Intern Med Date: 2007-10-16 Impact factor: 25.391
Authors: Faiza Safiruddin; Olivier M Vanderveken; Nico de Vries; Joachim T Maurer; Kent Lee; Quan Ni; Kingman P Strohl Journal: Eur Respir J Date: 2014-09-03 Impact factor: 16.671
Authors: Boris A Stuck; Madeline J L Ravesloot; Till Eschenhagen; H C W de Vet; J Ulrich Sommer Journal: Sleep Med Date: 2018-05-12 Impact factor: 3.492
Authors: Clemens Heiser; Armin Steffen; Maurits Boon; Benedikt Hofauer; Karl Doghramji; Joachim T Maurer; J Ulrich Sommer; Ryan Soose; Patrick J Strollo; Richard Schwab; Erica Thaler; Kirk Withrow; Alan Kominsky; Christopher Larsen; Eric J Kezirian; Jennifer Hsia; Stanley Chia; John Harwick; Kingman Strohl; Reena Mehra Journal: Eur Respir J Date: 2019-01-03 Impact factor: 16.671
Authors: Erica Thaler; Richard Schwab; Joachim Maurer; Ryan Soose; Christopher Larsen; Suzanne Stevens; Damien Stevens; Maurits Boon; Colin Huntley; Karl Doghramji; Tina Waters; Alan Kominsky; Armin Steffen; Eric Kezirian; Benedikt Hofauer; Ulrich Sommer; Kirk Withrow; Kingman Strohl; Clemens Heiser Journal: Laryngoscope Date: 2019-09-14 Impact factor: 3.325